Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001213900-24-098627
Filing Date
2024-11-14
Accepted
2024-11-14 19:00:26
Documents
1
Group Members
VIVO ASIA OPPORTUNITY FUND HOLDINGS, L.P.VIVO CAPITAL SURPLUS FUND VIII, L.P.VIVO CAPITAL VIII, LLCVIVO OPPORTUNITY CAYMAN, LLCVIVO OPPORTUNITY FUND HOLDINGS, L.P.VIVO OPPORTUNITY, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 2 TO SCHEDULE 13G ea022116106-13ga2vivo8_terns.htm SC 13G/A 182021
  Complete submission text file 0001213900-24-098627.txt   183866
Mailing Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301
Business Address 505 HAMILTON AVENUE, SUITE 200 PALO ALTO CA 94301 650 688 0818
Vivo Capital Fund VIII, L.P. (Filed by) CIK: 0001618788 (see all company filings)

EIN.: 471762196 | Fiscal Year End: 1231
Type: SC 13G/A

Mailing Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404
Business Address 1065 EAST HILLSDALE BLVD., SUITE 100 FOSTER CITY CA 94404 650-525-5535 EXT.101
Terns Pharmaceuticals, Inc. (Subject) CIK: 0001831363 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-92116 | Film No.: 241465123
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)